SCHEMBL20394281

SCHEMBL20394281

COc1ccccc1-c1cccnc1Oc1cnc(Cl)nc1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 7/20 0.47
L3MBTL1 Q9Y468 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
ELANE P08246 1/20 0.43
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
PPP1CA P62136 1/20 0.41
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PIN1 Q13526 1/20 0.40
PDE5A O76074 2/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394377 0.86 PDE10A (0.47) PDE10AL3MBTL1ELANELMNASMN1; SMN2
SCHEMBL20394226 0.85 PDE10A (0.47) PDE10AL3MBTL1POLBELANELMNA
SCHEMBL20394499 0.84 PDE10A (0.54) PDE10AL3MBTL1MEN1KMT2APOLB
SCHEMBL20394409 0.83 PDE10A (0.50) PDE10AL3MBTL1ELANELMNASMN1; SMN2
SCHEMBL20394322 0.83 PDE10A (0.45) PDE10AL3MBTL1KMT2APOLBELANE
SCHEMBL20406721 0.82 PDE10A (0.44) PDE10AL3MBTL1ELANELMNASMN1; SMN2
SCHEMBL20406679 0.81 PDE10A (0.48) PDE10AL3MBTL1ELANELMNASMN1; SMN2
SCHEMBL20755042 0.81 PDE10A (0.48) PDE10AL3MBTL1ELANELMNASMN1; SMN2
SCHEMBL20394287 0.81 PDE10A (0.51) PDE10AL3MBTL1ELANELMNASMN1; SMN2
SCHEMBL20406780 0.81 PDE10A (0.44) PDE10AL3MBTL1ELANELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA PDE10A 4605/4885L3MBTL1 1805/4885MEN1 2111/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA PDE10A 4605/4885L3MBTL1 1805/4885MEN1 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.